D. Western Therapeutics Institute, Inc.
Tokyo Stock Exchange 4576.T
D. Western Therapeutics Institute, Inc. EBITDA Margin for the year ending December 31, 2023: -181.06%
-
D. Western Therapeutics Institute, Inc. EBITDA Margin for the year ending December 31, 2022 was -87.20%, a -228.45% change year over year.
-
D. Western Therapeutics Institute, Inc. EBITDA Margin for the year ending December 31, 2021 was -26.55%, a 60.77% change year over year.
-
D. Western Therapeutics Institute, Inc. EBITDA Margin for the year ending December 31, 2020 was -67.67%, a -343.25% change year over year.
-
D. Western Therapeutics Institute, Inc. EBITDA Margin for the year ending December 31, 2019 was 27.82%.
| Date | EBITDA Margin | EBIT Margin | Depreciation and Amortization | EBIT |
|---|
Don’t Miss A Beat
| CEO | Mr. Yuichi Hidaka |
| IPO Date | Oct. 23, 2009 |
| Location | Japan |
| Headquarters | CK21 Hirokoujifushimi Bldg. |
| Employees | 21 |
| Sector | Health Care |
| Industries | |
D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. The company offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; DWR-2206, a regenerative medicine cell-product for bullous keratopathy; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM, ALC, ERM, and PVR membrane staining. It is also developing DW-5LBT, a lidocaine patch for neuropathic pain after shingles; K-321 to treat fuch endothelial corneal dystrophy which is in Phase III clinical trials; and H-1337, a multi-kinase inhibitor that has started Phase IIb clinical trials for the treatment of glaucoma/ocular hypertension. The company was founded in 1999 and is headquartered in Nagoya, Japan.
Past 5 years
StockViz Staff
February 2, 2025
Any question? Send us an email